Evidence map›Paper›PMID 33230417›Full record

ArticleNew microbes and new infections2020

SARS-CoV-2 and

M A M Iesa, M E M Osman, M A Hassan, A I A Dirar, N Abuzeid, J J Mancuso, R Pandey, A A Mohammed, M J Borad, H M Babiker and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New microbes and new infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Article
  6. Circulation of SARS-CoV-2 and Co-Infection withInfectious disease reports · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Exploring SARS-CoV-2 andFrontiers in immunology · 2023
    Article
  14. Article
  15. Article
  16. Prophylactic effect of cutaneous leishmaniasis against COVID-19: a case-control field assessment.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  17. Article
  18. Impact of COVID-19 and malaria coinfection on clinical outcomes: a retrospective cohort study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
    Article
  19. Article
  20. An Imported Case of AfebrileTropical medicine and infectious disease · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 4 countries.

M A M IesaDepartment of Physiology, Al Qunfudah Medical College, Umm Al Qura University, Mecca, Saudi Arabia.
M E M OsmanDepartment of Zoology, Faculty of Science, University of Khartoum, Khartoum, Sudan.
M A HassanDepartment of Translation Bioinformatics, DetaVax Biotech, Kayseri, Turkey.
A I A DirarGraduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto City, Japan.
N AbuzeidDepartment of Medical Microbiology, Faculty of Medical Laboratory of Sciences, Omdurman University, Khartoum, Sudan.
J J MancusoDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
R PandeyDepartment of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ, USA.
A A MohammedBiotechnology Department, Africa City of Technology, Khartoum, Sudan.
M J BoradDepartment of Medicine, Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, USA.
H M BabikerDepartment of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, AZ, USA.
E H E KonozyBiotechnology Department, Africa City of Technology, Khartoum, Sudan.
University of Arizona · USUniversity of Garden City · SDKumamoto University · JPMayo Clinic in Arizona · USThe University of Texas MD Anderson Cancer Center · USUmm al-Qura University · SAUniversity of Khartoum · SDUniversity of Science and Technology Omdurman · SD

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Teri L Bankhead · 1985 to 2026
$110.2M
6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) has caused significant morbidity and mortality and new cases are on the rise globally, yet malaria-endemic areas report statistically significant lower incidences. We identified potential shared targets for an immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by immune determinants' shared identities with

Indexed as

CD147 receptorepitopehomologyPlasmodium falciparumSARS-CoV-2

Identifiers

PMID33230417
PMCPMC7674012
OpenAlexW3105076578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.